trending Market Intelligence /marketintelligence/en/news-insights/trending/AhLtrXmqQ4gUBhLf20qKXw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lixte terminates license agreement with Taipei Medical University

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lixte terminates license agreement with Taipei Medical University

Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.

The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.